– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...
Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.
MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...
The Society of Interventional Radiology (SIR) announced that the CAPTAIN randomized clinical trial found that men with localized, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Windsong Radiology Group President Dr. Raja Cheruvu became ...
October 16, 2009 — Clinicians should consider magnetic resonance imaging (MRI) for men who have elevated prostate-specific antigen (PSA) levels or some other "worrisome" prostate cancer variable, but ...
Profound Medical (NASDAQ:PROF) highlighted what it described as growing clinical evidence, expanding software capabilities, and improving reimbursement dynamics for its MRI-guided “incision-free” ...
A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...
Mar 27, 2026, 7:45 AM ETProfound Medical Corp. (PROF), PRN:CA The TULSA Procedure, performed using the TULSA-PRO ® system, represents a major advancement in prostate care, and is used by physicians to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results